| Market Cap | 49.16M | P/E | - | EPS this Y | 17.50% | Ern Qtrly Grth | - |
| Income | -66.17M | Forward P/E | -0.80 | EPS next Y | 15.20% | 50D Avg Chg | -13.00% |
| Sales | 11.17M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | 0.31 | EPS next 5Y | - | 52W High Chg | -51.00% |
| Recommedations | 3.00 | Quick Ratio | 4.13 | Shares Outstanding | 38.26M | 52W Low Chg | 10.00% |
| Insider Own | 3.46% | ROA | -29.41% | Shares Float | 25.04M | Beta | 0.93 |
| Inst Own | 60.36% | ROE | -58.04% | Shares Shorted/Prior | 195.60K/243.05K | Price | 1.30 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 144,527 | Target Price | 1.75 |
| Oper. Margin | -1,492.71% | Earnings Date | Nov 7 | Volume | 28,668 | Change | -1.52% |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| HC Wainwright & Co. | Neutral | Aug 15, 24 |
| Leerink Partners | Market Perform | May 15, 24 |
| Jones Trading | Hold | May 15, 24 |
| HC Wainwright & Co. | Neutral | May 15, 24 |
| Guggenheim | Neutral | May 15, 24 |
| Stifel | Hold | May 15, 24 |
| HC Wainwright & Co. | Buy | Mar 22, 24 |
| HC Wainwright & Co. | Buy | Aug 8, 23 |
| HC Wainwright & Co. | Buy | Aug 3, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Quinn William P. | Chief Financial Offi.. Chief Financial Officer | Dec 12 | Buy | 0.97 | 11,829 | 11,474 | 36,272 | 12/13/23 |
| ENGLEMAN EDGAR | Director Director | Nov 29 | Sell | 0.88 | 148,884 | 131,018 | 251,522 | 12/01/23 |
| ENGLEMAN EDGAR | Director Director | Nov 21 | Sell | 0.9 | 1,943 | 1,749 | 269,587 | 11/22/23 |
| Vivo Capital VIII, LLC | 10% Owner 10% Owner | Nov 21 | Sell | 0.9 | 3,400 | 3,060 | 111,662 | 11/22/23 |
| ENGLEMAN EDGAR | Director Director | Nov 16 | Sell | 0.94 | 49,173 | 46,223 | 269,823 | 11/20/23 |
| Vivo Capital VIII, LLC | 10% Owner 10% Owner | Nov 16 | Sell | 0.94 | 86,054 | 80,891 | 113,119 | 11/20/23 |
| Novo Holdings A/S | 10% Owner 10% Owner | Jul 13 | Sell | 2.00 | 800,000 | 1,600,000 | 3,703,991 | 07/15/22 |
| Perez Edith A. | Chief Medical Office.. Chief Medical Officer | Dec 22 | Option | 2.8 | 35,714 | 99,999 | 37,042 | 02/01/22 |
| Perez Edith A. | Chief Medical Office.. Chief Medical Officer | Dec 22 | Buy | 10.65 | 1,328 | 14,143 | 1,328 | 02/01/22 |